Physician profile
Paul E Cundey, JR.
NPI 1235154907
$1,911.38
in general payments reported to CMS, 2019-2025
12 companies · $299 in 2025
The $299 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,405 · 2020: $43.44 · 2022: $66.95 · 2023: $78.30 · 2024: $18.19 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $395.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,069.37 | 2019 | |
| Boston Scientific Corporation | $257.83 | 2025 | Accolade Sr |
| Novartis Pharmaceuticals Corporation | $240.98 | 2019-2023 | |
| Pfizer INC. | $150.76 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $54.13 | 2019 | |
| Cardinal Health 200 LLC | $31.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.19 | 2024 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $16.85 | 2023 | Inpefa |
| Astellas Pharma US INC | $16.19 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.55 | 2019 | |
| Medtronic Vascular, INC. | $14.36 | 2019 | |
| Bardy Diagnostics, INC. | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Cundey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.